Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Fineline Cube Aug 21, 2026
Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Fineline Cube Aug 21, 2026
Company

Takeda Reports 3.7% YOY Revenue Growth in Q1 2023 Fiscal Year with Priority Products Driving Sales

Fineline Cube Aug 1, 2024

Japan-based multinational Takeda (TYO: 4502) has released its financial report for the fiscal year 2023...

Company Drug

BioNTech’s mRNA Cancer Immunotherapy BNT111 Achieves Primary Endpoint in Phase II Trial

Fineline Cube Jul 31, 2024

Germany-based BioNTech SE (NASDAQ: BNTX) has announced that its mRNA cancer immunotherapy BNT111, in combination...

Company

Pfizer Inc. Reports Q2 2024 Earnings with First Positive Growth Since Q4 2022 Peak

Fineline Cube Jul 31, 2024

Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has announced its financial results for...

Company

Merck’s Q2 2024 Earnings Miss Estimates as China Market Downturn Surprises

Fineline Cube Jul 31, 2024

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has reported its financial results for the...

Company Drug

FibroGen Inc. Enters Restructuring Mode After Late-Stage Trial Failures for Pamrevlumab

Fineline Cube Jul 31, 2024

US-based biotechnology company FibroGen Inc. (NASDAQ: FGEN), which maintains significant operations in China, is initiating...

Company Deals

National Comprehensive Cancer Network Renews Partnership with Medlive for Oncology Guidelines Access in China

Fineline Cube Jul 31, 2024

The National Comprehensive Cancer Network (NCCN), a leading non-profit academic organization in the US, has...

Policy / Regulatory

China’s NHSA and NHC to Integrate Village Clinics into Basic Medical Insurance System

Fineline Cube Jul 31, 2024

The National Healthcare Security Administration (NHSA) and the National Health Commission (NHC) of China have...

Company Deals

Shenzhen-Based Synthetica Secures Initial Funding to Advance Oncolytic Bacteria Pipeline

Fineline Cube Jul 31, 2024

Synthetica, a pioneering developer of live bacteria drugs based in Shenzhen, has announced the successful...

Policy / Regulatory

China’s NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs

Fineline Cube Jul 31, 2024

In a meeting chaired by Party Secretary and Director of the National Medical Products Administration...

Company Drug

Bio-Thera Solutions’ Bevacizumab Biosimilar Avzivi Receives European Commission Approval

Fineline Cube Jul 31, 2024

Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced that its biosimilar version of Roche’s Avastin, Avzivi...

Company Drug

Gan & Lee Pharmaceuticals Gains Market Foothold in Algeria with Insulin Product Approvals

Fineline Cube Jul 31, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company, has announced that it has...

Company Medical Device

MicroPort Scientific’s Fully Biodegradable Cardiac Stent Earns NMPA Nod

Fineline Cube Jul 31, 2024

Shanghai-based medical device titan MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...

Company Deals

Suzhou Hanerxi Medical Secures Series B Funding to Build Asia’s Largest Pen Injector Facility

Fineline Cube Jul 31, 2024

Suzhou Hanerxi Medical Device Development Co., Ltd, a specialist in pen syringe technology based in...

Company

Brii Bioscience’s US Partner VBI Vaccines Initiates Bankruptcy Reorganization

Fineline Cube Jul 31, 2024

Brii Biosciences Ltd (HKG: 2137), a biopharmaceutical company based in China, has announced that its...

Company Drug

Cutia Therapeutics’ CU-30101 NDA Accepted for Review by China’s NMPA

Fineline Cube Jul 31, 2024

Cutia Therapeutics (HKG: 2487), a company specializing in dermatological treatments, has announced that the National...

Policy / Regulatory

China’s NMPA Issues Guidelines for Onsite Inspections of Medical Device Companies

Fineline Cube Jul 31, 2024

The National Medical Products Administration (NMPA) of China has released the “Guidelines for Onsite Inspection...

Company

WuXi AppTec’s H1 2024 Financials Reflect Decline Amid Biosecure Act Challenges

Fineline Cube Jul 30, 2024

China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec (HKG: 2359) has reported a subdued...

Company Deals

Roche Completes Acquisition of LumiraDx’s Point-of-Care Solutions Business

Fineline Cube Jul 30, 2024

Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO) has announced the...

Company

Philips Posts 2% Q2 2024 Sales Growth, Boosted by North American Demand

Fineline Cube Jul 30, 2024

Royal Philips (NYSE: PHG), the Dutch electronics giant, reported its financial results for the second...

Company Deals

GSK Enters into Strategic Partnership with Flagship Pioneering to Develop Novel Medicines and Vaccines

Fineline Cube Jul 30, 2024

UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has announced a new partnership with...

Posts pagination

1 … 366 367 368 … 711

Recent updates

  • CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors
  • LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval
  • China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect
  • Boehringer Ingelheim Upgrades China Strategy with New Shanghai R&D Center, Deepening Investment in Pharma and Animal Health
  • Ultomiris Wins NMPA Approval for PNH in China, Bringing Long‑Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Company

Boehringer Ingelheim Upgrades China Strategy with New Shanghai R&D Center, Deepening Investment in Pharma and Animal Health

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.